Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

Shikha Gaur, Yafan Wang, Leo Kretzner, Linling Chen, Terence Yen, Xiwei Wu, Yate Ching Yuan, Mark Davis, Yun Yen

研究成果: 雜誌貢獻文章

36 引文 (Scopus)

摘要

CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is designed to concentrate and slowly release camptothecin in tumors over an extended period of time. Tumor biopsy and blood samples collected from patients with advanced solid malignancies before and after CRLX101 treatment are subjected to immunohistochemistry and pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF decreased after CRLX101 treatment. The expressions of these proteins are inversely proportional with survival duration of the patients. The Drug Metabolism Enzymes and Transporters (DMET) array shows an allele frequency in patients similar to global populations with none of the SNPs associated with toxicity. The results suggest that the observed lower toxicity is not likely to be due to different genotypes in SNPs. CRLX101 demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-refractory solid tumor malignancies presumably by inhibition of proliferation and angiogenesis correlating with tumor growth inhibition. From the Clinical Editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics. The expressions of key proteins that are inversely proportional with survival duration of the patients decreased after treatment with CRLX101, a camptothecin slow-release nanoparticle conjugate. This anti-tumor activity in heavily pre-treated and treatment resistant solid tumors, promises a novel therapeutic approach.
原文英語
頁(從 - 到)1477-1486
頁數10
期刊Nanomedicine: Nanotechnology, Biology, and Medicine
10
發行號7
DOIs
出版狀態已發佈 - 十月 1 2014
對外發佈Yes

指紋

Pharmacodynamics
Camptothecin
Nanoparticles
Tumors
Neoplasms
Therapeutics
Toxicity
Pharmacogenetics
Proteins
Single Nucleotide Polymorphism
Oncology
Biopsy
Cyclodextrins
Immunohistochemistry
IT-101
Pharmacogenomic Testing
Metabolism
Refractory materials
Vascular Endothelial Growth Factor A
Survival

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science
  • Medicine(all)

引用此文

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. / Gaur, Shikha; Wang, Yafan; Kretzner, Leo; Chen, Linling; Yen, Terence; Wu, Xiwei; Yuan, Yate Ching; Davis, Mark; Yen, Yun.

於: Nanomedicine: Nanotechnology, Biology, and Medicine, 卷 10, 編號 7, 01.10.2014, p. 1477-1486.

研究成果: 雜誌貢獻文章

Gaur, Shikha ; Wang, Yafan ; Kretzner, Leo ; Chen, Linling ; Yen, Terence ; Wu, Xiwei ; Yuan, Yate Ching ; Davis, Mark ; Yen, Yun. / Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. 於: Nanomedicine: Nanotechnology, Biology, and Medicine. 2014 ; 卷 10, 編號 7. 頁 1477-1486.
@article{a173f32c71a247589970eaad0bebcdbb,
title = "Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer",
abstract = "CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is designed to concentrate and slowly release camptothecin in tumors over an extended period of time. Tumor biopsy and blood samples collected from patients with advanced solid malignancies before and after CRLX101 treatment are subjected to immunohistochemistry and pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF decreased after CRLX101 treatment. The expressions of these proteins are inversely proportional with survival duration of the patients. The Drug Metabolism Enzymes and Transporters (DMET) array shows an allele frequency in patients similar to global populations with none of the SNPs associated with toxicity. The results suggest that the observed lower toxicity is not likely to be due to different genotypes in SNPs. CRLX101 demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-refractory solid tumor malignancies presumably by inhibition of proliferation and angiogenesis correlating with tumor growth inhibition. From the Clinical Editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics. The expressions of key proteins that are inversely proportional with survival duration of the patients decreased after treatment with CRLX101, a camptothecin slow-release nanoparticle conjugate. This anti-tumor activity in heavily pre-treated and treatment resistant solid tumors, promises a novel therapeutic approach.",
keywords = "Camptothecin, HIF-1α, Immunohistochemistry, Nanoparticle, Polymer conjugate, Solid tumor, Topoisomerase 1",
author = "Shikha Gaur and Yafan Wang and Leo Kretzner and Linling Chen and Terence Yen and Xiwei Wu and Yuan, {Yate Ching} and Mark Davis and Yun Yen",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.nano.2014.04.003",
language = "English",
volume = "10",
pages = "1477--1486",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

AU - Gaur, Shikha

AU - Wang, Yafan

AU - Kretzner, Leo

AU - Chen, Linling

AU - Yen, Terence

AU - Wu, Xiwei

AU - Yuan, Yate Ching

AU - Davis, Mark

AU - Yen, Yun

PY - 2014/10/1

Y1 - 2014/10/1

N2 - CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is designed to concentrate and slowly release camptothecin in tumors over an extended period of time. Tumor biopsy and blood samples collected from patients with advanced solid malignancies before and after CRLX101 treatment are subjected to immunohistochemistry and pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF decreased after CRLX101 treatment. The expressions of these proteins are inversely proportional with survival duration of the patients. The Drug Metabolism Enzymes and Transporters (DMET) array shows an allele frequency in patients similar to global populations with none of the SNPs associated with toxicity. The results suggest that the observed lower toxicity is not likely to be due to different genotypes in SNPs. CRLX101 demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-refractory solid tumor malignancies presumably by inhibition of proliferation and angiogenesis correlating with tumor growth inhibition. From the Clinical Editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics. The expressions of key proteins that are inversely proportional with survival duration of the patients decreased after treatment with CRLX101, a camptothecin slow-release nanoparticle conjugate. This anti-tumor activity in heavily pre-treated and treatment resistant solid tumors, promises a novel therapeutic approach.

AB - CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is designed to concentrate and slowly release camptothecin in tumors over an extended period of time. Tumor biopsy and blood samples collected from patients with advanced solid malignancies before and after CRLX101 treatment are subjected to immunohistochemistry and pharmacogenomics. The expression of Topoisomerase-1, Ki-67, CaIX, CD31 and VEGF decreased after CRLX101 treatment. The expressions of these proteins are inversely proportional with survival duration of the patients. The Drug Metabolism Enzymes and Transporters (DMET) array shows an allele frequency in patients similar to global populations with none of the SNPs associated with toxicity. The results suggest that the observed lower toxicity is not likely to be due to different genotypes in SNPs. CRLX101 demonstrates a promising anti-tumor activity in heavily pre-treated or treatment-refractory solid tumor malignancies presumably by inhibition of proliferation and angiogenesis correlating with tumor growth inhibition. From the Clinical Editor: In this cancer treatment study clinical samples collected from patients were subjected to immunohistochemistry and pharmacogenomics. The expressions of key proteins that are inversely proportional with survival duration of the patients decreased after treatment with CRLX101, a camptothecin slow-release nanoparticle conjugate. This anti-tumor activity in heavily pre-treated and treatment resistant solid tumors, promises a novel therapeutic approach.

KW - Camptothecin

KW - HIF-1α

KW - Immunohistochemistry

KW - Nanoparticle

KW - Polymer conjugate

KW - Solid tumor

KW - Topoisomerase 1

UR - http://www.scopus.com/inward/record.url?scp=84912151114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912151114&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2014.04.003

DO - 10.1016/j.nano.2014.04.003

M3 - Article

C2 - 24768630

AN - SCOPUS:84912151114

VL - 10

SP - 1477

EP - 1486

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 7

ER -